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INTRODUCTION: Sodium bicarbonate (NaHCO3) is a well-established nutritional ergogenic aid that is typically ingested as a beverage
or consumed in gelatin capsules. Whilst capsules may delay NaHCO3 release and reduce gastrointestinal (GI) side-effects compared
with a beverage, it is currently unclear whether capsule size may influence acid-base responses and GI symptoms following
supplementation. AIM: To determine the effects of NaHCO3 supplementation administered in different sized capsules on acid-base
responses, GI symptoms and palatability. METHODS: Ten healthy males (mean ± SD: age 20 ± 2 y; height 1.80 ± 0.09 m; weight 78.0 ±
11.9 kg) underwent three testing sessions whereby 0.3 g∙kg–1 body mass NaHCO3 was consumed in either small (size 3), medium
(size 0) or large (size 000) capsules. Capillary blood samples were procured pre-ingestion and every 10 min post-ingestion for 180
min. Blood samples were analysed using a Radiometer (Radiometer ABL800, Denmark) to determine blood bicarbonate
concentration ([HCO3–]) and potential hydrogen (pH). Gastrointestinal (GI) symptoms were measured using a questionnaire at the
same timepoints, whereas palatability was recorded pre-consumption. RESULTS: Capsule size had a significant effect on lag time
(the time [HCO3-] changed Tlag) and the timing of peak blood [HCO3–](Tmax). Bicarbonate Tlag was significantly higher in the large
(28 ± 4 min) compared with the small (13 ± 2 min) sized capsules (P = 0.009). Similarly, Tmax was significantly lower in the small
capsule (13 ± 2 min) compared with both the medium (22 ± 6 min; P = 0.005) and large (28 ± 4 min; P = 0.001) sized capsules. The GI
symptom scores were similar for small (3 ± 3 AU,), medium (5 ± 3 AU) and large (3 ± 3 AU) sized capsules, with no significant
difference between symptom scores (F = 1.3, P = 0.310). Similarly, capsule size had no effect on palatability (F = 0.8, P = 0.409),
with similar scores between different capsule sizes. CONCLUSION: Small capsule sizes led to quicker Tlag and Tmax of blood [HCO3–]
compared to medium and large capsules, suggesting that individuals could supplement NaHCO3 in smaller capsules if they aim to
increase buffering capacity more quickly.
  
 Contribution to the field
Whilst the use of both liquids and capsules to deliver sodium bicarbonate to research participants and athletes, seeking an
ergogenic benefit are common, no one has investigated the size of the capsule. We undertook this work to determine which best
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INTRODUCTION: Sodium bicarbonate (NaHCO3) is a well-established nutritional ergogenic 
aid that is typically ingested as a beverage or consumed in gelatine capsules. Whilst capsules 
may delay the release of NaHCO3 and reduce gastrointestinal (GI) side-effects compared with 
a beverage, it is currently unclear whether capsule size may influence acid-base responses 
and GI symptoms following supplementation. AIM: To determine the effects of NaHCO3 
supplementation administered in different sized capsules on acid-base responses, GI 
symptoms and palatability. METHODS: Ten healthy males (mean ± SD: age 20 ± 2 y; height 
1.80 ± 0.09 m; weight 78.0 ± 11.9 kg) underwent three testing sessions whereby 0.3 g∙kg–1 
body mass NaHCO3 was consumed in either small (size 3), medium (size 0) or large (size 
000) capsules. Capillary blood samples were procured pre-ingestion and every 10 min post-
ingestion for 180 min. Blood samples were analysed using a Radiometer (Radiometer 
ABL800, Denmark) to determine blood bicarbonate concentration ([HCO3–]) and potential 
hydrogen (pH). Gastrointestinal (GI) symptoms were measured using a questionnaire at the 
same timepoints, whereas palatability was recorded pre-consumption. RESULTS: Capsule 
size had a significant effect on lag time (the time [HCO3-] changed Tlag) and the timing of peak 
blood [HCO3–](Tmax). Bicarbonate Tlag was significantly higher in the large (28 ± 4 min) 
compared with the small (13 ± 2 min) sized capsules (P = 0.009). Similarly, Tmax was 
significantly lower in the small capsule (94 ± 24 min) compared with both the medium (141 ± 
27 min; P < 0.001) and large (121 ± 29 min; P < 0.001) sized capsules. The GI symptom 
scores were similar for small (3 ± 3 AU,), medium (5 ± 3 AU) and large (3 ± 3 AU) sized 
capsules, with no significant difference between symptom scores (F = 1.3, P = 0.310). 
Similarly, capsule size had no effect on palatability (F = 0.8, P = 0.409), with similar scores 
between different capsule sizes. CONCLUSION: Small capsule sizes led to quicker Tlag and 
Tmax of blood [HCO3–] concentration compared to medium and large capsules, suggesting that 
individuals could supplement NaHCO3 in smaller capsules if they aim to increase extracellular 






Sodium bicarbonate (NaHCO3) is an extensively researched nutritional ergogenic aid, shown 
to be particularly effective in improving short-duration (~1-10 min) high intensity exercise 
performance (Matson and Tran, 1993, Carr, Hopkins and Gore, 2011, Gough et al., 2018). 
Supplementation with NaHCO3 serves to enhance endogenous bicarbonate buffering 
capacity, by inducing temporary elevations in extracellular bicarbonate concentrations and 
resultantly, enhancing efflux of hydrogen cations (H+) from skeletal muscle. Consequently, an 
improved H+ efflux attenuates muscular fatigue and has been shown to positively impact 
multiple performance measures such as total work done (McNaughton, 1992a), power output 
(Kilding, Overton and Gleave, 2012) and time to exhaustion (Higgins, James and Price, 2013) 
and recovery between exercise bouts (Gough et al 2019). 
The ergogenic potential of NaHCO3 is widely acknowledged (Close et al 2016), but some 
individuals suffer adverse gastrointestinal symptoms (Burke and Pyne, 2007, Hilton et al., 
2019) (GIS) that may be deleterious to performance (Deb et al 2018; Saunders et al 2014). 
Recently, some authors have attempted to find strategies to alleviate the severity of GIS by 
using delayed release (2019) and enterically coated capsules (Hilton et al., 2020a). This 
strategy builds on the concept of reducing GIS by delaying the release of HCO3 into the 
stomach thereby limiting carbon dioxide production that occurs when NaHCO3 is ingested 
(Ibekwe et al., 2008, Oliveira, Saunders and Artioli, 2018). At present these coatings make 
this ergogenic strategy expensive. Indeed, the most frequently used ingestion strategy is 
gelatine capsule delivery of NaHCO3. This is both a cheap alternative, improves the palatability 
compared to the traditional solution, and is widely used by athletes and researchers.  
Encapsulation may result in reductions in the HCO3 lost in the stomach and bring about 
comparable acid-base changes using smaller doses than required from aqueous delivery 
(Oliveira et al., 2018). There is however some suggestion that encapsulation may impair or 
slow bicarbonate availability, through decreased gut transit time (Barbosa, Conway and 





gastro-resistant properties of different capsule forms and their subsequent effects on 
bicarbonate bioavailability have begun to be elucidated (Hilton et al., 2019, 2020a, 2020b), 
the effects of the physical properties of capsules such as their overall size, (and therefore 
surface area) on bicarbonate bioavailability remains unclear. 
In the pharmaceutical industry, the bioavailability of a substance is carefully considered as 
part of delivery vehicle testing, and is affected by size, surface area and surface area/volume 
of the capsule. Furthermore, there is a direct relationship between the surface area of a 
substance and its dissolution rate, specifically, an increase in total surface area of a delivery 
vehicle in contact with the gastrointestinal fluids causes an increase in the dissolution rate 
(Ashford 2017). Indeed, the dissolution of substances from capsules is a complex function of 
four key factors: (1) the rates of  the dissolution of the capsule shell, (2) the rate of penetration 
of the gastrointestinal fluids into the gastrointestinal mass, (3) the rate at which the mass 
disaggregates in the gastrointestinal fluids and (4) the rate of dissolution of the dispersed 
substance particles (Ashford, 2017). Such factors are rarely considered in the delivery of 
ergogenic aids, despite these processes being highly variable and subject to potentially large 
inter-individual variation (Sparks et al., 2017). Given the considerable evidence of the 
ergogenic effects of NaHCO3 and the widespread use of capsules as an ingestion strategy, 
understanding how capsule size (and therefore surface area) impacts bioavailability is of high 
importance for optimising pre-exercise ingestion timing (Boegman et al., 2020). Therefore, the 
aim of this study was to determine the effects of NaHCO3 supplementation administered in 
different sized capsules on blood acid-base responses, GIS and palatability. 
Method 
Participants 
Ten recreationally active males with the following (Mean ± SD) characteristics volunteered for 
this study: age, 20 ± 2 y; height, 1.8 ± 0.2 m; body mass, 78.0 ± 11.9 kg. All participants 
undertook regular (≥ 3 days·wk-1) exercise for at least 30 min per session. Following medical 





any nutritional supplements or prescription medication.  The protocol was explained in full and 
questions were answered before the participants gave written, informed consent to participate 
in the study. The study was approved by the Departmental Research Ethics Committee. 
Study design  
Participants visited the laboratory on three separate occasions after an overnight fast and at 
the same time of day (Reilly et al., 1990). Visits were separated by between 24-72 hours to 
allow acid base balance variables to return to normal (Siegler et al., 2009; Bishop et al. 2004). 
Participants maintained their habitual diet before experimental testing (Spencer, Bishop and 
Lawrence, 2004; McNaughton et al. 2011) and refrained from alcohol ingestion and strenuous 
exercise at least 24 hours before each visit. During the initial visit, height (Seca, Germany) 
and body mass (Holtain, UK) were recorded before participants consumed 300 mg·kg–1 body 
mass NaHCO3 in gelatine capsules (Bulk Powders™, Colchester, UK). This dose was chosen 
based on previous findings of improved exercise performance and is a dose widely recognised 
to be ergogenic within the literature (McNaughton, 1992; McNaughton & Cedaro, 1991; 
McNaughton et al. 1991; Gough et al. 2018). Capsule sizes were administered using  a 
repeated measures crossover design, following the use of a Latin square to determine trial 
order allocation for participants (Kuehl, 2000). The three trials used either standard small (size 
3), medium (size 0) and large (size 000) capsules. Each capsule contained 0.4, 0.8 and 1.6 g 
NaHCO3 and the mean number of capsules consumed was 59 ± 9, 29 ± 4 and 15 ± 2 capsules 
which equated to a total capsule surface area for the bolus of 23.3 ± 3.5, 20.7 ± 3.1, and 16.4 
± 2.5 cm2 for the small, medium and large capsule sizes respectively. Capsules were 
consumed with 400 ml of water which was at room temperature (18 C). Capsule palatability 
was recorded immediately post-ingestion. Participants remained seated for 180 min while 
blood acid-base responses and GI symptoms were monitored throughout.  
 
Acid-base responses 
During experimental protocol, exposure response was established through mapping the time 





was chosen as it is a method widely used in the exogenous buffering intervention literature 
(McNaughton 1992; Bishop et al., 2004; Carr et al., 2011; Boegman et al., 2020; Hilton et al., 
2020b), and is a recognised method for blood gas analysis. Capillary blood was drawn pre-
ingestion and then post-ingestion every 10 minutes for 3 hours, an established protocol for 
examining acid-base changes following exogenous buffer ingestion (Gough et al., 2018; Hilton 
et al., 2019; Hilton et al., 2020a). Samples were collected in 100 μL heparin-coated glass 
capillary tubes (Radiometer Medical Ltd, Denmark) using an aseptic technique and were 
analysed immediately using a blood gas analyser (Radiometer ABL800 BASIC, Denmark). 
These data were then used to determine the peak in [HCO3-] change (Cmax), the absolute 
change in [HCO3-](Cmax), the time to reach Cmax (Tmax), the area under the concentration-time 
curve (AUC), and the time lag (Tlag). The Tlag was defined as an increase in [HCO3-] beyond 
normal daily variability (Hilton et al., 2020a).    
 
Gastrointestinal symptoms and palatability 
At the same time points, GI symptoms were measured using a 9-item questionnaire which 
included stomach cramping, flatulence, nausea, belching, stomach-ache, diarrhoea, vomiting, 
bowel urgency and stomach bloating (Carr et al., 2011). Each symptom was measured on an 
11-point scale, whereby ‘0 = no symptom’ and ‘10 = severe symptom’. Palatability was 
recorded immediately post-ingestion using a 9-point hedonic scale, where ‘1 = extremely 
dislike’ and ‘9 = extremely like’ (Jones, Peryam and Thurstone, 1955). 
 
Statistical Analysis  
All data were assessed for normality the Shapiro–Wilk test and by visual inspection of the 
normality plots (Grafen and Hails, 2002). Blood acid-base responses (HCO3- and pH) and GI 
symptoms were analysed using two-way (condition × time) analysis of variance (ANOVA) with 
repeated-measures. A general linear model ANOVA was used to analyse absolute acid-base 
values (peak blood [HCO3-], time-to-peak blood [HCO3-], peak blood pH, time-to- peak blood 





statistical significance was set at p < 0.05. Effect sizes were reported as partial eta-squared 
(ηp2) and are described as trivial (< 0.20), small (ηp2 = 0.20-0.49) moderate (ηp2 = 0.50-0.79) 
and large (≥ 0.80), respectively (Cohen, 1988). 
 
Results 
Blood bicarbonate responses 
There were significant increases in blood [HCO3–] (F = 93.2, p < 0.001, ηp2 = 0.91) in all 
NaHCO3 conditions compared with pre-consumption values (Figure 1b). Capsule size had no 
significant effect on [HCO3–] (F = 2.3, p = 0.151, ηp2 = 0.21) post-consumption, although a 
significant condition × time interaction was observed (F = 3.3, p = 0.014, ηp2 = 0.27), 
suggesting that the large capsules changed [HCO3-] more slowly in the initial part of the post 
ingestion period, and the medium sized capsule sustained [HCO3-] for longer (Figure 1b). 
 
[INSERT FIGURE 1 NEAR HERE] 
 
Capsule size also had a significant effect on Tlag (F = 3.8, p = 0.043, ηp2 = 0.30), with 
significantly longer times in the large (28 ± 4 min) compared with the small (13 ± 2 min) sized 
capsules (p = 0.009). Similarly, capsule size had a significant effect on Tmax (F = 157.6, p = 
0.000, ηp2 = 0.94), with significantly shorter times in the small capsule compared with both the 
medium (p = 0.000) and large (p = 0.000) sized capsules (Table 1). No significant differences 
were observed for Cmax (F = 0.6, p = 0.574, ηp2 = 0.06), ∆Cmax (F = 0.3 p = 0.731, ηp2 = 0.03) 
or AUC (F = 2.1, p = 0.148, ηp2 = 0.19) between conditions (Table 1). There appeared to be 
a large inter-individual variability in response to the capsule ingestion (Figure 2). 
 
[INSERT TABLE 1 NEAR HERE] 
 [INSERT FIGURE 2 NEAR HERE] 
 





Blood pH increased in all NaHCO3 conditions (F = 41.5, p < 0.001, ηp2 = 0.82) compared with 
pre-consumption values (Figure 1a). Capsule size had a significant effect on blood pH (F = 
3.9, p = 0.040, ηp2 = 0.30) overall, although no significant condition × time interaction was 
shown for blood pH (F = 0.9, p = 0.628, ηp2 = 0.09; Figure 1a). There were no significant 
differences in either peak blood pH (F = 1.5, p = 0.249, ηp2 = 0.14) and time-to-peak blood pH 
(F = 1.9, p = 0.181, ηp2 = 0.17) between conditions. 
 
Gastrointestinal symptoms and palatability 
Gastrointestinal symptom scores were similar for small (3 ± 3 AU,), medium (5 ± 3 AU) and 
large (3 ± 3 AU) sized capsules, with no significant difference between symptom scores (F = 
1.3, p = 0.310, ηp2 = 0.12). Similarly, capsule size had no effect on palatability (F = 0.8, p = 
0.461, ηp2 = 0.08), with similar scores between different capsule sizes (Figure 3). Palatability 
scores ranged from 1–9 AU, 1–9 AU and 1–7 AU for small, medium and large capsules, 
respectively. 
 
[INSERT FIGURE 3 NEAR HERE] 
 
Discussion 
This study showed that different capsule sizes led to differences in Tlag and Tmax of blood 
[HCO3-], without affecting the absolute increases in circulating HCO3- or AUC of the increases 
over 180 min. Since Tlag (versus large capsules) and Tmax was shorter (versus medium and 
large capsules) for small capsules, and palatability was similar albeit also without affecting GI 
symptoms, this suggests that smaller capsules may be a better form of ingestion for individuals 
wishing to increase their extracellular buffering capacity more quickly. Those using capsules 
to administer NaHCO3 should also be cognisant of the trade off in palatability and participant 
comfort due to the inverse relationship between capsule size and the number of capsules 
needed to deliver a potentially ergogenic dose (Hayakawa et al., 2016).  Despite the mean 





considerable individual variability in responses, similar to those previously reported (Sparks et 
al 2015, Jones et al., 2016, Oliveira et al., 2020). 
Alternative forms of NaHCO3 ingestion will lead to different pharmacokinetic profiles, with the 
most common forms in solution or gelatine capsules, with apparently different HCO3- kinetics 
(Oliveira et al., 2020). Enterically-coated and delayed-release forms also lead to different 
HCO3- kinetics compared to gelatine capsules (Hilton et al., 2019, 2020a, 2020b). These novel 
data now show that different sizes of gelatine capsules lead to different blood HCO3- kinetics, 
with quicker increases and time to reach peak values with smaller capsules. Previously the 
dissolution rates for individual size 0 and 3 gelatine capsules have been observed to be similar 
at around 100 s (Chiwele et al., 2000). However, in the present study, the large differences 
between the number of capsules ingested between capsule size conditions results in 
considerable differences in the total surface area of the ingested substance. Consequently, 
the greater total surface area of the smaller capsules, is likely to liberate their contents quicker. 
There were no differences between the medium and large-sized capsules shown here. For 
those intending to ensure the start of exercise coincides with Cmax, these data suggest that 
individuals could adapt the capsule size in which they ingest NaHCO3 depending on when 
they can supplement. The present study also standardised the temperature of the fluid 
ingested with the capsules, but consuming hotter fluids is likely to reduce Tmax, and colder 
fluids are likely to increase Tmax. (Chiwele et al., 2000). At present, no studies have considered 
the temperature of the fluid on the pharmokinetics of extracellular buffers such a NaHCO3, but 
athletes and sports nutrition practitioners should be aware that this is likely to alter the 
expected time duration at which NaHCO3 should be ingested prior to exercise. It would be of 
interest to determine whether enteric-coated versions of these capsules also lead to different, 
and more favourable, HCO3- kinetics following ingestion.  
Side-effect associated with NaHCO3 ingestion include nausea, vomiting, GI discomfort, 
diarrhoea and headache (McNaughton, 1992a, 1992b). There has been some suggestion that 
minimising neutralisation of stomach acids due to the increased NaHCO3 load might lead to 





why enterically-coated and delayed-release forms of NaHCO3 reduce the incidence and 
severity of GI disturbances compared to gelatine capsules (Hilton et al., 2019, 2020a, 2020b). 
Despite the different HCO3- profiles here, there were no differences in the side-effect symptom 
scores between the different capsule sizes suggesting individuals need not concern 
themselves with side-effects when choosing which size of gelatine capsule to use for NaHCO3 
supplementation. Nonetheless, further work should elucidate whether enteric-coated versions 
of these different capsule sizes can reduce their side-effects since discomfort associated with 
NaHCO3 can be ergolytic to exercise performance (Saunders et al., 2014).  
A limitation of this study is that we only analysed the time course of blood HCO3- and pH 
kinetics following NaHCO3 supplementation in different capsules sizes. It could have been 
interesting to determine whether different exercise performance responses were shown 
between the capsules. Nonetheless, it could be hypothesised that similar performance 
improvements would be shown seen if exercise was performed at TTP since there were no 
differences between capsules sizes for peak HCO3- change, absolute HCO3- at peak, and the 
HCO3- AUC. It is possible that performance differences might be found should standardised 
ingestion times be employed prior to exercise, since Tmax was different between capsules 
sizes. Therefore, it is important to ensure that individual responses to the specific type of 
capsules that are being used, are determined in order to optimise the pre-exercise timing of 
their ingestion.  
In conclusion, small capsule sizes led to quicker Tlag and Tmax of blood [HCO3-] compared to 
medium and large capsules, without affecting absolute increases in circulating HCO3- or AUC. 
Palatability and GI symptoms were similar between all capsule sizes. Individuals could 
supplement NaHCO3 in smaller capsules if they aim to increase extracellular buffering 
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Table 1. Mean (SD) bicarbonate kinetic variables following the consumption of 0.3 gkg–1 body 






Variable Small Medium Large 
Tlag (min) 13 ± 2 22 ± 6  28 ± 4a 
Cmax (mmol∙L–1) 31.7 ± 1.7 32.1 ± 1.5 31.8 ± 1.4 
∆Cmax (mmol∙L–1) 7.1 ± 1.1 6.7 ± 1.4 6.8 ± 0.8 
Tmax (min) 94 ± 24b 141 ± 27b 121 ± 29b 
AUC (mmol∙min∙L–1) 5316 ± 256 5373 ± 264 5239 ± 263 
Notes: Tlag, lag time; Cmax, peak bicarbonate concentration; ∆Cmax, change 
in peak bicarbonate concentration; Tmax, time-to-peak bicarbonate 
concentration; AUC, area under the curve. (a) Denotes a significant 
difference between the large and small capsules (p < 0.05); (b) Denotes a 






Figure 1. Mean (±SD) temporal blood pH (a) and bicarbonate concentration [HCO3–] responses, 
following the consumption of 0.3 gkg–1 body mass NaHCO3 in small, medium and large-sized 
capsules. (*) denotes a condition*time interaction between small and medium capsules where 
p <0.05. () denotes a condition*time interaction between small and large capsules where p 
<0.05. (◼) denotes a condition*time interaction between medium and large capsules where p 
<0.05. 
 
Figure 2. Mean (±SD) and individual peak changes in blood bicarbonate concentration [HCO3-] 
(Cmax) following the consumption of 0.3 gkg–1 body mass NaHCO3 in small, medium and 
large-sized capsules. Small markers represent individual responses, and large markers 
represent mean data for each capsule condition. X and Y whiskers represent the SD of the 
sample in each condition for time-to-peak [HCO3-] (Tmax) and Cmax respectively. 
 
Figure 3. Mean (±SD) palatability scores following the consumption of 0.3 gkg–1 body mass 
NaHCO3 in small, medium and large sized capsules. 
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